BioCentury | Feb 18, 2008
Strategy

Functional GI compounds

Functional GI compounds Constipation Company Product Description Target Indication Status Progenics (NASDAQ:PGNX)/ Methylnaltrexone Peripheral mu opioid Mu opioid receptor Opioid-induced Apr 30 Wyeth (NYSE:WYE) (MNTX) receptor antagonist constipation (OIC) PDUFA Adolor (NASDAQ:ADLR)/ GlaxoSmithKline(LSE:GSK; NYSE:GSK) Entereg...
BC Week In Review | Oct 6, 2003
Clinical News

Dexloxiglumide: Phase III

In 2 placebo-controlled Phase III trials in more than 1,400 women, dexloxiglumide failed to meet the primary endpoint of subject global assessment, a measurement of a patient's overall evaluation of abdominal discomfort, pain and altered...
BC Extra | Oct 1, 2003
Clinical News

Forest discontinues IBS compound

FRX discontinued development of dexloxiglumide to treat constipation predominant irritable bowel syndrome (IBS) based on results from two placebo-controlled Phase III trials in more than 1,400 women. The compound, a cholecystokinin (CCK1) receptor antagonist, failed...
BioCentury | Nov 18, 2002
Product Development

Plumbing plays

Plumbing plays Company Product Description Indication Status Milestone Adolor Alvimopan Gut-specific mu opioid receptor antagonist Post-operative ileus (POI) and chronic opioid-induced bowel dysfunction (OBD) Ph III POI NDA 2H03 Alizyme ALT-1251 renzapride Mixed serotonin receptor...
BC Week In Review | Oct 22, 2001
Clinical News

Dexloxiglumide: Phase II

FRX reported that in a Phase II trial of 405 patients with IBS, dexloxiglumide had a higher response rate than placebo, although the difference was not statistically significant. Statistical significance was seen in a subgroup...
BC Extra | Oct 18, 2001
Clinical News

FRX Phase II dexloxiglumide data

Forest Laboratories (FRX) said that in a Phase II trial of 405 patients with irritable bowel syndrome (IBS), its dexloxiglumide had a higher response rate than placebo, although the difference was not statistically significant. However,...
BC Week In Review | Aug 14, 2000
Company News

Forest Laboratories, Rotta Research Laboratorium S.p.A. deal

Rotta granted FRX U.S. marketing and development rights to dexloxiglumide , a cholecytokinin type A (CCKA) receptor antagonist, to treat irritable bowel syndrome. Dexloxiglumide increases gastric emptying and intestinal motility and modulates intestinal sentitivity to distension,...
Items per page:
1 - 7 of 7